Karina K. Noskova
Karina K. Noskova has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Anna Valeryevna Kagramanova
Loginov Moscow Clinical Scientific Center; Research Institute for Healthcare Organization and Medical Management
5 shared publications - Asfold I. Parfenov
Loginov Moscow Clinical Scientific Center
5 shared publications - Albina A. Lishchinskaya
Loginov Moscow Clinical Scientific Center
3 shared publications - Galina A. Dudina.
Moscow Clinical Scientific and Practical Center named after A.S. Loginov, Moscow Healthcare Department
3 shared publications - Natalia A. Bodunova
Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia
3 shared publications - Oleg V. Knyazev
Moscow Clinical Scientific Center named after Loginov
3 shared publications
Latest Publications
- Open Access
- 22 September 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (3) , 39-52
Multimodal endoscopic ultrasound diagnostic evaluation of pancreatic cystic lesions
Aim. To optimize the differential diagnosis of pancreatic cystic lesions by introducing novel endoscopic ultrasound (EUS) technologies into clinical practice.Materials and Methods. The study analyzed the outcomes of multimodal diagnostic evaluation in 424 patients with pancreatic cystic lesions who underwent EUS.Results. In 328 cases (77.4%), conventional B-mode EUS provided sufficient diagnostic information. In 96 cases (22.6%), contrast enhancement was required: 59 patients (61.5%) underwent assessment of contrast uptake by the cyst wall, septa, and solid components; 25 (26%) only by the wall and septa; and in 12 (12.5%) assessment was made ofnodular components of the pancreatic cystic lesions. Retrospective analysis demonstrated that contrast-enhanced EUS increased overall diagnostic accuracy for differentiating cystic neoplasms from post-necrotic pseudocysts by 14.7%, improved detection of solid components within cystic lesions by 11.3%, and enhanced identification of cystic adenocarcinomas or intraductal papillary mucinous neoplasms (IPMNs) associated with adenocarcinoma by 9.9%. The integration of contrast enhancement into the EUS diagnostic algorithm significantly reduced the number of fineneedle aspirations (FNA) required.Conclusion. Both our clinical experience and data from international research underscore the necessity of incorporating multimodal EUS into the diagnostic work-up for cystic pancreatic lesions. Based on the study, an algorithm was developed for applying novel EUS technologies in the differential diagnosis of pancreatic cystic tumors.
- 22 September 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (3) , 39-52
Open AccessMultimodal endoscopic ultrasound diagnostic evaluation of pancreatic cystic lesions
Aim. To optimize the differential diagnosis of pancreatic cystic lesions by introducing novel endoscopic ultrasound (EUS) technologies into clinical practice.Materials and Methods. The study analyzed the outcomes of multimodal diagnostic evaluation in 424 patients with pancreatic cystic lesions who underwent EUS.Results. In 328 cases (77.4%), conventional B-mode EUS provided sufficient diagnostic information. In 96 cases (22.6%), contrast enhancement was required: 59 patients (61.5%) underwent assessment of contrast uptake by the cyst wall, septa, and solid components; 25 (26%) only by the wall and septa; and in 12 (12.5%) assessment was made ofnodular components of the pancreatic cystic lesions. Retrospective analysis demonstrated that contrast-enhanced EUS increased overall diagnostic accuracy for differentiating cystic neoplasms from post-necrotic pseudocysts by 14.7%, improved detection of solid components within cystic lesions by 11.3%, and enhanced identification of cystic adenocarcinomas or intraductal papillary mucinous neoplasms (IPMNs) associated with adenocarcinoma by 9.9%. The integration of contrast enhancement into the EUS diagnostic algorithm significantly reduced the number of fineneedle aspirations (FNA) required.Conclusion. Both our clinical experience and data from international research underscore the necessity of incorporating multimodal EUS into the diagnostic work-up for cystic pancreatic lesions. Based on the study, an algorithm was developed for applying novel EUS technologies in the differential diagnosis of pancreatic cystic tumors.
- Open Access
- 22 September 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (3) , 53-62
Intraductal papillary mucinous neoplasms of the pancreas associated with ductal carcinoma as two distinct clinical entities
Aim. To analyze current perspectives on the concept of malignant progression in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and to outline the most prospective research trends in this area.Materials and Methods. A literature review and an analysis of data from the cancer registry of Moscow were conducted. Results. The paper summarizes key molecular genetic studies from recent decades. Using surgical specimen data coded according to ICD-O in Moscow for the years 2023–2024, the main challenges in the histopathological diagnosis of IPMN with associated invasive carcinoma are discussed.Conclusion. Genomic alterations in IPMNs of the pancreas, as background lesions for pancreatic ductal adenocarcinoma, reflect their genetic heterogeneity and carry significant clinical implications for understanding the polyclonal theory of carcinogenesis, as well as for identifying novel therapeutic targets and approaches. The invasive component associated with IPMN is frequently genetically independent based on its molecular profile.
- 22 September 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (3) , 53-62
Open AccessIntraductal papillary mucinous neoplasms of the pancreas associated with ductal carcinoma as two distinct clinical entities
Aim. To analyze current perspectives on the concept of malignant progression in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and to outline the most prospective research trends in this area.Materials and Methods. A literature review and an analysis of data from the cancer registry of Moscow were conducted. Results. The paper summarizes key molecular genetic studies from recent decades. Using surgical specimen data coded according to ICD-O in Moscow for the years 2023–2024, the main challenges in the histopathological diagnosis of IPMN with associated invasive carcinoma are discussed.Conclusion. Genomic alterations in IPMNs of the pancreas, as background lesions for pancreatic ductal adenocarcinoma, reflect their genetic heterogeneity and carry significant clinical implications for understanding the polyclonal theory of carcinogenesis, as well as for identifying novel therapeutic targets and approaches. The invasive component associated with IPMN is frequently genetically independent based on its molecular profile.
- Open Access
- 22 September 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (3) , 12-30
International consensus on diagnosing and managing pancreatic serous and mucinous cystic neoplasms
In 2023, with the approval of the leadership of the Hepato-Pancreato-Biliary Association of Commonwealth of Independent States, a consensus study was initiated and conducted on the diagnosis, management, and follow-up of patients with serous and mucinous neoplasms of the pancreas. Based on an extensive literature review, responses to each of the 22 questions posed were formulated and compiled into a Consensus Document. A total of 44 experts representing 27 institutions across 9 countries participated in the preparation of the Consensus. The Delphi method was employed for voting, and ultimately, including the results of votes on selected statements during the final conference, consensus was achieved on all questions.
- 22 September 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (3) , 12-30
Open AccessInternational consensus on diagnosing and managing pancreatic serous and mucinous cystic neoplasms
In 2023, with the approval of the leadership of the Hepato-Pancreato-Biliary Association of Commonwealth of Independent States, a consensus study was initiated and conducted on the diagnosis, management, and follow-up of patients with serous and mucinous neoplasms of the pancreas. Based on an extensive literature review, responses to each of the 22 questions posed were formulated and compiled into a Consensus Document. A total of 44 experts representing 27 institutions across 9 countries participated in the preparation of the Consensus. The Delphi method was employed for voting, and ultimately, including the results of votes on selected statements during the final conference, consensus was achieved on all questions.
- Open Access
- 26 March 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (2) , 128-136
Prevention of venous thromboembolic complications in patients with ulcerative colitis
Background. The incidence of venous thromboembolic complications (VTEC) in patients with inflammatory bowel diseases is approximately 3 times higher than in the general population and leads to a 2-fold increase in the risk of mortality. The risk of VTEC is the highest during the patient's hospital stay. Aim. To compare the overall VTEC risk in inpatients with ulcerative colitis (UC) with and without VTEC primary prevention. Materials and methods. In 2020, anticoagulant therapy was used for patients with UC in the case of acute venous thrombosis, and in 2022, primary thromboprophylaxis in patients with UC with moderate and high VTEC risk was based on the data obtained from the previous analysis of VTEC risk factors in inpatients with inflammatory bowel diseases. VTEC prophylaxis in UC patients was performed with a low molecular weight heparin (LMWH) – calcium nadroparin – at a dose of 0.3 mL (2850 IU anti-Xa) per day subcutaneously throughout the stay in the round-the-clock hospital. Results. In 2020, venous thrombosis was diagnosed in 16 (1.8%) patients with UC, including venous thrombosis of the lower extremities in 3 (0.3%) patients, venous thrombosis of the upper extremities in 7 (0.8%), pulmonary embolism in 2 (0.2%), and combined thrombosis in 4 (0.5%). In 2022, venous thrombosis was diagnosed in 5 (0.5%) patients with UC, including venous thrombosis of the lower extremities in 1 (0.1%) patient, venous thrombosis of the upper extremities in 3 (0.3%), and pulmonary embolism in 1 (0.1%). Thus, primary prevention with an LMWH significantly reduces the risk of VTEC in hospitalized patients with UC (relative risk 0.285, 95% confidence interval 0.103–0.774; χ2=6.917; p=0.009). Conclusion. Our results demonstrate that primary prevention with an LMWH significantly reduces the risk of VTEC in patients with UC hospitalized in a round-the-clock hospital.
- 26 March 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (2) , 128-136
Open AccessPrevention of venous thromboembolic complications in patients with ulcerative colitis
Background. The incidence of venous thromboembolic complications (VTEC) in patients with inflammatory bowel diseases is approximately 3 times higher than in the general population and leads to a 2-fold increase in the risk of mortality. The risk of VTEC is the highest during the patient's hospital stay. Aim. To compare the overall VTEC risk in inpatients with ulcerative colitis (UC) with and without VTEC primary prevention. Materials and methods. In 2020, anticoagulant therapy was used for patients with UC in the case of acute venous thrombosis, and in 2022, primary thromboprophylaxis in patients with UC with moderate and high VTEC risk was based on the data obtained from the previous analysis of VTEC risk factors in inpatients with inflammatory bowel diseases. VTEC prophylaxis in UC patients was performed with a low molecular weight heparin (LMWH) – calcium nadroparin – at a dose of 0.3 mL (2850 IU anti-Xa) per day subcutaneously throughout the stay in the round-the-clock hospital. Results. In 2020, venous thrombosis was diagnosed in 16 (1.8%) patients with UC, including venous thrombosis of the lower extremities in 3 (0.3%) patients, venous thrombosis of the upper extremities in 7 (0.8%), pulmonary embolism in 2 (0.2%), and combined thrombosis in 4 (0.5%). In 2022, venous thrombosis was diagnosed in 5 (0.5%) patients with UC, including venous thrombosis of the lower extremities in 1 (0.1%) patient, venous thrombosis of the upper extremities in 3 (0.3%), and pulmonary embolism in 1 (0.1%). Thus, primary prevention with an LMWH significantly reduces the risk of VTEC in hospitalized patients with UC (relative risk 0.285, 95% confidence interval 0.103–0.774; χ2=6.917; p=0.009). Conclusion. Our results demonstrate that primary prevention with an LMWH significantly reduces the risk of VTEC in patients with UC hospitalized in a round-the-clock hospital.
- Open Access
- 9 November 2022
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 26 (5) , 177-187
International experience of laboratory methods in the cervical cancer screening
Cervical cancer (CC) is a serious health problem all over the world. CC is a fully preventable disease; however, it remains one of the leading causes of death among women with carcinomas. The screening helps to reduce morbidity and mortality. Two tests are used as screening tests in the world: сervical cytology and detection of human papillomavirus (HPV). Cervical cytology (Pap test) is a traditional test of CC screening. Two types of Pap test are used in modern laboratory practice: liquid and traditional methods. HPV testing is now used as the primary screening tool for СС in some countries. However, a key factor in effective screening is the coverage of the population and the organization of the screening. Immunocytochemical examination is an additional method used to improve the accuracy of diagnosis, p16/Ki-67 dual staining. This review focuses on the laboratory methods used in the world practice of screening. The literature search for this review was conducted using PubMed, MedLine and Embase.
- 9 November 2022
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 26 (5) , 177-187
Open AccessInternational experience of laboratory methods in the cervical cancer screening
Cervical cancer (CC) is a serious health problem all over the world. CC is a fully preventable disease; however, it remains one of the leading causes of death among women with carcinomas. The screening helps to reduce morbidity and mortality. Two tests are used as screening tests in the world: сervical cytology and detection of human papillomavirus (HPV). Cervical cytology (Pap test) is a traditional test of CC screening. Two types of Pap test are used in modern laboratory practice: liquid and traditional methods. HPV testing is now used as the primary screening tool for СС in some countries. However, a key factor in effective screening is the coverage of the population and the organization of the screening. Immunocytochemical examination is an additional method used to improve the accuracy of diagnosis, p16/Ki-67 dual staining. This review focuses on the laboratory methods used in the world practice of screening. The literature search for this review was conducted using PubMed, MedLine and Embase.
- Open Access
- 15 February 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (2) , 172-179
Frequency and risk factors for thromboembolic complications in patients with inflammatory bowel diseases
Background. Inflammatory bowel diseases (IBD) are characterized by chronic immune inflammation of the mucous membrane and/or the thickness of the intestinal wall, and are also accompanied by disorders of the blood clotting system and the development of a hypercoagulation state. Aim. To identify the frequency of thromboembolic complications (TEC) in IBD patients and to determine the influence of acquired and inherited hypercoagulation factors that contribute to the development of TEС. Materials and methods. The clinical status of 1,238 IBD patients who were treated in 2019 was evaluated. Of these, 748 patients with ulcerative colitis (UC) and 490 patients with Crohn's disease (CD). Among UC patients, there were 369 (49.3%) men and 379 (50.7%) women. In 10.1% of patients with UC, there were clinically significant feasibility studies. There were 227 (46.3%) men and 263 (53.7%) women among patients with CD; 7.3% of patients with CD had clinically significant feasibility studies. Results. In general 112 (9.0%) of 1,238 IBD patients had clinically significant feasibility studies. Among patients with UC (n=748), 76 (10.2%) showed clinically significant feasibility studies. Among patients with CD (n=490), 36 (7.3%) had a feasibility study. Of 112 IBD patients with clinically significant TEC, 45 (40.2%) had genetic polymorphisms that increase affinity for fibrinogen, increase platelet aggregation, and contribute to a decrease in the activity of folate cycle enzymes, including methylenetetrahydrofolate reductase, which may be manifested by a moderate increase in homocysteine levels. Of the 45 IBD patients with clinically significant TEC due to inherited factors, 30 (66.6%) patients had UC, 15 (33.7%) patients had CD (hazard ratio 1.038, 95% confidence interval 0.7461.444; 2=0.049; p=0.83921); 67 (59.8%) patients with IBD who had clinically significant TEC did not have genetic polymorphisms leading to hypercoagulation. Conclusion. Based on the analysis, we can conclude that such risk factors for the development of TEC as the status of a smoker, long bed rest, taking hormonal contraceptives, varicose veins of the lower extremities, high activity of the disease, glucocorticoids therapy, the extent of intestinal damage in patients with IBD, genetic factors, should be taken into account by gastroenterologists in the treatment of patients with UC and CD. The hereditary factor of hypercoagulation equally affects the development of TEC, both in patients with UC and CD.
- 15 February 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (2) , 172-179
Open AccessFrequency and risk factors for thromboembolic complications in patients with inflammatory bowel diseases
Background. Inflammatory bowel diseases (IBD) are characterized by chronic immune inflammation of the mucous membrane and/or the thickness of the intestinal wall, and are also accompanied by disorders of the blood clotting system and the development of a hypercoagulation state. Aim. To identify the frequency of thromboembolic complications (TEC) in IBD patients and to determine the influence of acquired and inherited hypercoagulation factors that contribute to the development of TEС. Materials and methods. The clinical status of 1,238 IBD patients who were treated in 2019 was evaluated. Of these, 748 patients with ulcerative colitis (UC) and 490 patients with Crohn's disease (CD). Among UC patients, there were 369 (49.3%) men and 379 (50.7%) women. In 10.1% of patients with UC, there were clinically significant feasibility studies. There were 227 (46.3%) men and 263 (53.7%) women among patients with CD; 7.3% of patients with CD had clinically significant feasibility studies. Results. In general 112 (9.0%) of 1,238 IBD patients had clinically significant feasibility studies. Among patients with UC (n=748), 76 (10.2%) showed clinically significant feasibility studies. Among patients with CD (n=490), 36 (7.3%) had a feasibility study. Of 112 IBD patients with clinically significant TEC, 45 (40.2%) had genetic polymorphisms that increase affinity for fibrinogen, increase platelet aggregation, and contribute to a decrease in the activity of folate cycle enzymes, including methylenetetrahydrofolate reductase, which may be manifested by a moderate increase in homocysteine levels. Of the 45 IBD patients with clinically significant TEC due to inherited factors, 30 (66.6%) patients had UC, 15 (33.7%) patients had CD (hazard ratio 1.038, 95% confidence interval 0.7461.444; 2=0.049; p=0.83921); 67 (59.8%) patients with IBD who had clinically significant TEC did not have genetic polymorphisms leading to hypercoagulation. Conclusion. Based on the analysis, we can conclude that such risk factors for the development of TEC as the status of a smoker, long bed rest, taking hormonal contraceptives, varicose veins of the lower extremities, high activity of the disease, glucocorticoids therapy, the extent of intestinal damage in patients with IBD, genetic factors, should be taken into account by gastroenterologists in the treatment of patients with UC and CD. The hereditary factor of hypercoagulation equally affects the development of TEC, both in patients with UC and CD.
- Open Access
- 15 December 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (12) , 1435-1442
Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy
Aim. To conduct comparative analysis of histological remission in patients with moderate and severe ulcerative colitis (UC), receiving biological therapy vedolizumab, mesenchymal stem cell (MSC) treatment and combined stem cells and vedolizumab therapy. Materials and methods. We studied biopsies of 75 patients with total or left-sided moderate and severe ulcerative colitis, divided into groups depending on treatment. The first group of UC patients (n=29) received stem cell therapy 2 mln per kg; the second group of UC patients (n=27) received vedolizumab and the third group (n=19) MSC and vedolizumab. The efficacу of treatment was assessed by C reactive protein (CRP), Mayo score (MS), fecal calprotectin (FC) and Geboes score (GS). Results. We determined medium correlation between basic FC and MS before treatment (r=0.6605, p0.05). After 12 weeks of treatment in the first group of UC patients (n=29) CRP was 7.82.1 mg/l, FC 409.344.85 g/g, medium GS 1.20.1 points. After 12 weeks of treatment in the second group of UC patients (n=27) CRP was 8.41.4 mg/l, FC 435.547.3 g/g, medium GS 1.350.15 points. After 12 weeks of treatment in the third group of UC patients (n=19) CRP was 6.41.1 mg/l, FC 290.617.5 g/g, medium GS 0.90.1 points. We proved strong direct relationship between FC and GS after 12 weeks of treatment in UC patients, receiving MSC (r=0.8392, p0.05). The statistically significant majority of patients, achieved histological remission, have less than 5-year duration of disease. Conclusion. Our study showed that clinical and endoscopic remission in UC patients does not always correlate with histological remission. Combined anti-cytokine and stem cells therapy contributes to achieve deep remission and decrease mucosa inflammation rather than single MSC or vedolizumab treatment. Deep remission could be achieved by earlier start of biological therapy. FC could be a predictor and marker of mucosa healing and histological remission
- 15 December 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (12) , 1435-1442
Open AccessHistological remission of ulcerative colitis with combined anti-cytokine and cell therapy
Aim. To conduct comparative analysis of histological remission in patients with moderate and severe ulcerative colitis (UC), receiving biological therapy vedolizumab, mesenchymal stem cell (MSC) treatment and combined stem cells and vedolizumab therapy. Materials and methods. We studied biopsies of 75 patients with total or left-sided moderate and severe ulcerative colitis, divided into groups depending on treatment. The first group of UC patients (n=29) received stem cell therapy 2 mln per kg; the second group of UC patients (n=27) received vedolizumab and the third group (n=19) MSC and vedolizumab. The efficacу of treatment was assessed by C reactive protein (CRP), Mayo score (MS), fecal calprotectin (FC) and Geboes score (GS). Results. We determined medium correlation between basic FC and MS before treatment (r=0.6605, p0.05). After 12 weeks of treatment in the first group of UC patients (n=29) CRP was 7.82.1 mg/l, FC 409.344.85 g/g, medium GS 1.20.1 points. After 12 weeks of treatment in the second group of UC patients (n=27) CRP was 8.41.4 mg/l, FC 435.547.3 g/g, medium GS 1.350.15 points. After 12 weeks of treatment in the third group of UC patients (n=19) CRP was 6.41.1 mg/l, FC 290.617.5 g/g, medium GS 0.90.1 points. We proved strong direct relationship between FC and GS after 12 weeks of treatment in UC patients, receiving MSC (r=0.8392, p0.05). The statistically significant majority of patients, achieved histological remission, have less than 5-year duration of disease. Conclusion. Our study showed that clinical and endoscopic remission in UC patients does not always correlate with histological remission. Combined anti-cytokine and stem cells therapy contributes to achieve deep remission and decrease mucosa inflammation rather than single MSC or vedolizumab treatment. Deep remission could be achieved by earlier start of biological therapy. FC could be a predictor and marker of mucosa healing and histological remission
- Open Access
- 1 May 2021
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (Supplement) , S379
P359 Influence of the nature of immunosuppressive therapy in patients with inflammatory bowel diseases on the level of immunoglobulins G after a Coronavirus Infection
Currently, there are differences in the results of international studies and treatment outcomes in patients with inflammatory bowel disease (IBD) and COVID-19. Further research is needed to help answer the questions: do IBD patients have an increased risk of contracting SARS-CoV-2? Do IBD patients have more severe COVID-19 outcomes? Does IBD therapy increase the risk of infection? Do any IBD treatments protect against COVID-19? To study the effect of immunosuppressors, genetically engineered biologics, and janus kinase blockers on the level of SARS-CoV-2 class G immunoglobulins in IBD patients who underwent COVID-19. . The level of SARS-CoV-2 class G immunoglobulins was analyzed in 66 patients with IBD after COVID-19 infection. Male 28 (42.4%) of women 38 (57.6 per cent). The median age was 39±4.2 years. The duration of the anamnesis ranged from 1 to 8 years (Iu 4 years). The patients were divided into two groups, depending on the therapy performed: Group 1 (n=31) received long-term (more than 1 year) immunosuppressants (azathioprine/6-mercaptopurine/tofacitinib), group 2 (n=35) received anti-TNF-α therapy. The level of SARS-CoV-2 class G immunoglobulins was determined by the immunochemiluminescence method. After 4-6 weeks later, after a twice negative smear of PCR from the nose and oropharynx for SARS-CoV-2, in patients (n=31) receiving anti-relapse therapy with systemic IBD (azathioprine/6-mercaptopurine) and selective (tofacitinib) immunosuppressants, the average level of Ig G was 44.1±9.8 U/l. Among patients with IBD receiving anti-TNF-a drugs (n=35), the average level of class G immunoglobulins was 133.6±14.4 U/l. The difference was statistically significant (p=0.000003). The level of class G immunoglobulins 3-4 weeks after the COVID-19 infection was significantly higher in IBD patients who received anti-TNF-α drugs.
- 1 May 2021
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (Supplement) , S379
Open AccessP359 Influence of the nature of immunosuppressive therapy in patients with inflammatory bowel diseases on the level of immunoglobulins G after a Coronavirus Infection
Currently, there are differences in the results of international studies and treatment outcomes in patients with inflammatory bowel disease (IBD) and COVID-19. Further research is needed to help answer the questions: do IBD patients have an increased risk of contracting SARS-CoV-2? Do IBD patients have more severe COVID-19 outcomes? Does IBD therapy increase the risk of infection? Do any IBD treatments protect against COVID-19? To study the effect of immunosuppressors, genetically engineered biologics, and janus kinase blockers on the level of SARS-CoV-2 class G immunoglobulins in IBD patients who underwent COVID-19. . The level of SARS-CoV-2 class G immunoglobulins was analyzed in 66 patients with IBD after COVID-19 infection. Male 28 (42.4%) of women 38 (57.6 per cent). The median age was 39±4.2 years. The duration of the anamnesis ranged from 1 to 8 years (Iu 4 years). The patients were divided into two groups, depending on the therapy performed: Group 1 (n=31) received long-term (more than 1 year) immunosuppressants (azathioprine/6-mercaptopurine/tofacitinib), group 2 (n=35) received anti-TNF-α therapy. The level of SARS-CoV-2 class G immunoglobulins was determined by the immunochemiluminescence method. After 4-6 weeks later, after a twice negative smear of PCR from the nose and oropharynx for SARS-CoV-2, in patients (n=31) receiving anti-relapse therapy with systemic IBD (azathioprine/6-mercaptopurine) and selective (tofacitinib) immunosuppressants, the average level of Ig G was 44.1±9.8 U/l. Among patients with IBD receiving anti-TNF-a drugs (n=35), the average level of class G immunoglobulins was 133.6±14.4 U/l. The difference was statistically significant (p=0.000003). The level of class G immunoglobulins 3-4 weeks after the COVID-19 infection was significantly higher in IBD patients who received anti-TNF-α drugs.
- Open Access
- 15 February 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (2) , 145-149
Screening for celiac disease among patients of the gastroenterological profile
Aim. To determine the frequency of celiac disease (CD) among gastroenterological patients and criteria for its active detection. Materials and methods. 1.358 patients referred for gastroenterologist consultation from 2016 to 2019 was conducted, of which 140 had CD (339 males 24.9%; 1019 females 75.1%). The average age was 40.415.4 (1886 years). All patients were determined anti-TTG IgA, IgG, and analyzed the clinical symptoms and analysis. The results were subjected to statistical processing Statistica 13.3 (StatSoft Inc., USA). Results. In patients without CD (1218 people), high level of anti-TTG IgA and IgG was observed in 59 (4.8%), an increase in anti-TTG IgA in 54 (4.4%), and anti-TTG IgG in 38 patients (3.1%). The CD diagnosis confirmed in 51 patients (4.2%). The main symptoms were diarrhea (88%), abdominal pain (60.7%), bloating (73.8%), nausea (40.3%), weight loss (44.3%). Anemia was determined in 31.6%, serum iron 33%, hypoproteinemia 12.6%, hypoalbuminemia 12%, hypokalemia 5.48%, hypocalcemia 21.9%. An increase in the level of AST 14.5%, ALT 14.6%. Comparative analysis showed that in the group with newly detected CD, anemia, malabsorption syndrome, increase AST, ALT were significantly more frequent than in patients with normal antibodies, which confirms the need to detect CD among patients with these laboratory abnormalities. Conclusion. The incidence of CD among patients with a gastroenterological symptoms was 4.2%. Analysis of clinical and laboratory data has shown that a comprehensive analysis of clinical symptoms and laboratory indicators at the stage of primary treatment will allow timely identification of CD patients and prescribe GFD.
- 15 February 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (2) , 145-149
Open AccessScreening for celiac disease among patients of the gastroenterological profile
Aim. To determine the frequency of celiac disease (CD) among gastroenterological patients and criteria for its active detection. Materials and methods. 1.358 patients referred for gastroenterologist consultation from 2016 to 2019 was conducted, of which 140 had CD (339 males 24.9%; 1019 females 75.1%). The average age was 40.415.4 (1886 years). All patients were determined anti-TTG IgA, IgG, and analyzed the clinical symptoms and analysis. The results were subjected to statistical processing Statistica 13.3 (StatSoft Inc., USA). Results. In patients without CD (1218 people), high level of anti-TTG IgA and IgG was observed in 59 (4.8%), an increase in anti-TTG IgA in 54 (4.4%), and anti-TTG IgG in 38 patients (3.1%). The CD diagnosis confirmed in 51 patients (4.2%). The main symptoms were diarrhea (88%), abdominal pain (60.7%), bloating (73.8%), nausea (40.3%), weight loss (44.3%). Anemia was determined in 31.6%, serum iron 33%, hypoproteinemia 12.6%, hypoalbuminemia 12%, hypokalemia 5.48%, hypocalcemia 21.9%. An increase in the level of AST 14.5%, ALT 14.6%. Comparative analysis showed that in the group with newly detected CD, anemia, malabsorption syndrome, increase AST, ALT were significantly more frequent than in patients with normal antibodies, which confirms the need to detect CD among patients with these laboratory abnormalities. Conclusion. The incidence of CD among patients with a gastroenterological symptoms was 4.2%. Analysis of clinical and laboratory data has shown that a comprehensive analysis of clinical symptoms and laboratory indicators at the stage of primary treatment will allow timely identification of CD patients and prescribe GFD.
- 1 January 2021
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 10 (4) , 12
Blood biomarkers and computed tomography for differential diagnosis of pancreatic cancer and chronic pancreatitis
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить возможность комплексной дифференциальной диагностики рака поджелудочной железы (РПЖ) и хронического панкреатита (ХП) с применением комбинации онкомаркеров РЭА, CA 19-9 и CA 242 и неинвазивной оценки микроциркуляторного русла при помощи мультиспиральной компьютерной томографии (МСКТ) с внутривенным контрастированием. МАТЕРИАЛ И МЕТОДЫ В исследование включены 193 больных РПЖ и ХП, проходивших обследование и лечение в отделении патологии поджелудочной железы и желчевыводящих путей ГБУЗ «МКНЦ им. А.С. Логинова ДЗМ» в 2017—2019 гг. РЕЗУЛЬТАТЫ Эффективность CA 19-9, CA 242 и РЭА как раздельно интерпретируемых биомаркеров, так и при их совместном использовании оценивали по кривым ROC. При сравнении групп РПЖ и ХП выявлено, что значения чувствительности равны 74%, специфичности — 92%, площадь под кривой (AUC) — 0,83 для CA 19-9; 60%, 82%, 0,71 для CA 242; 68%, 70%, 0,69 для РЭА. При подсчете параметров ROC-кривой при комбинации всех трех онкомаркеров выявлено увеличение AUC до 0,88; чувствительности до 84%, однако наблюдалось некоторое снижение специфичности по сравнению с определением только CA19-9 — 78%. В результате обработки результатов КТ выявлено, что среднее значение Mgrad у пациентов группы РПЖ статистически значимо выше (26,5±8,6 HU), чем у пациентов группы ХП (13,9±5,1 HU), p=0,0001. Анализ полученных значений Mgrad в исследованных группах позволил вычислить пороговое значение для дифференциальной диагностики РПЖ: Mgrad=20 HU. Массив значений Mgrad выше данного показателя статистически значимо чаще отмечен у пациентов с РПЖ (p=0,001). ЗАКЛЮЧЕНИЕ Совместное определение в сыворотке крови уровней онкомаркеров CA 19-9, CA 242 и РЭА имеет больший показатель чувствительности и значение AUC ROC-кривой, чем использование одного из указанных онкомаркеров для дифференциальной диагностики рака поджелудочной железы и хронического панкреатита. Мультиспиральная компьютерная томография с внутривенным контрастированием и оценкой Mgrad эффективнее, чем только мультиспиральная компьютерная томография с внутривенным контрастированием для дифференциальной диагностики рака поджелудочной железы и хронического панкреатита.
- 1 January 2021
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 10 (4) , 12
Blood biomarkers and computed tomography for differential diagnosis of pancreatic cancer and chronic pancreatitis
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить возможность комплексной дифференциальной диагностики рака поджелудочной железы (РПЖ) и хронического панкреатита (ХП) с применением комбинации онкомаркеров РЭА, CA 19-9 и CA 242 и неинвазивной оценки микроциркуляторного русла при помощи мультиспиральной компьютерной томографии (МСКТ) с внутривенным контрастированием. МАТЕРИАЛ И МЕТОДЫ В исследование включены 193 больных РПЖ и ХП, проходивших обследование и лечение в отделении патологии поджелудочной железы и желчевыводящих путей ГБУЗ «МКНЦ им. А.С. Логинова ДЗМ» в 2017—2019 гг. РЕЗУЛЬТАТЫ Эффективность CA 19-9, CA 242 и РЭА как раздельно интерпретируемых биомаркеров, так и при их совместном использовании оценивали по кривым ROC. При сравнении групп РПЖ и ХП выявлено, что значения чувствительности равны 74%, специфичности — 92%, площадь под кривой (AUC) — 0,83 для CA 19-9; 60%, 82%, 0,71 для CA 242; 68%, 70%, 0,69 для РЭА. При подсчете параметров ROC-кривой при комбинации всех трех онкомаркеров выявлено увеличение AUC до 0,88; чувствительности до 84%, однако наблюдалось некоторое снижение специфичности по сравнению с определением только CA19-9 — 78%. В результате обработки результатов КТ выявлено, что среднее значение Mgrad у пациентов группы РПЖ статистически значимо выше (26,5±8,6 HU), чем у пациентов группы ХП (13,9±5,1 HU), p=0,0001. Анализ полученных значений Mgrad в исследованных группах позволил вычислить пороговое значение для дифференциальной диагностики РПЖ: Mgrad=20 HU. Массив значений Mgrad выше данного показателя статистически значимо чаще отмечен у пациентов с РПЖ (p=0,001). ЗАКЛЮЧЕНИЕ Совместное определение в сыворотке крови уровней онкомаркеров CA 19-9, CA 242 и РЭА имеет больший показатель чувствительности и значение AUC ROC-кривой, чем использование одного из указанных онкомаркеров для дифференциальной диагностики рака поджелудочной железы и хронического панкреатита. Мультиспиральная компьютерная томография с внутривенным контрастированием и оценкой Mgrad эффективнее, чем только мультиспиральная компьютерная томография с внутривенным контрастированием для дифференциальной диагностики рака поджелудочной железы и хронического панкреатита.